Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco S&P 500 Momentum ETF (SPMO) vs Viatris Inc (VTRS) Price & Performance

Invesco S&P 500 Momentum ETFTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Invesco S&P 500 Momentum ETF vs Viatris Inc — how do they compare? Invesco S&P 500 Momentum ETF trades at $150.3, while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc pays a 2.89% dividend while Invesco S&P 500 Momentum ETF pays none. Which is the better fit depends on your goals.

SPMOVTRS
Sector
Broad Market / FactorHealth
52-Week High
$161.66$17.86
52-Week Low
$107.84$9.49
Market Cap
$19.09B
Enterprise Value
$31.21B
Dividend Yield
2.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco S&P 500 Momentum ETF

SPMO trades at $150.47, up 0.5% with a bullish technical outlook supported by strong moving average signals. The ETF has delivered exceptional performance, averaging 37% annual returns over three years according to The Motley Fool (2026-09-06). Recent momentum factor strength and concentrated tech exposure drive its market-beating track record, though this introduces higher volatility during sector rotations.

The outlook remains positive with structural momentum advantages and lower drawdowns than the S&P 500. Key risks include concentrated technology sector exposure and sensitivity to market rotations. Analyst sentiment leans bullish with multiple buy recommendations citing the ETF's rules-based momentum strategy and cost efficiency at 0.13% expense ratio.

Viatris Inc

Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.

The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Invesco S&P 500 Momentum ETF

SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.

Read more on SPMO

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS